These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14599408)

  • 21. Intracellular accumulation of human immunodeficiency virus protease inhibitors.
    Khoo SH; Hoggard PG; Williams I; Meaden ER; Newton P; Wilkins EG; Smith A; Tjia JF; Lloyd J; Jones K; Beeching N; Carey P; Peters B; Back DJ
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3228-35. PubMed ID: 12234849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
    Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
    AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
    Casado JL; Perez-Elías MJ; Antela A; Sabido R; Martí-Belda P; Dronda F; Blazquez J; Quereda C
    AIDS; 1998 Jul; 12(11):F131-5. PubMed ID: 9708403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
    Kirk O; Katzenstein TL; Gerstoft J; Mathiesen L; Nielsen H; Pedersen C; Lundgren JD
    AIDS; 1999 Jan; 13(1):F9-16. PubMed ID: 10207539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
    Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
    Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
    AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
    Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.
    Barreiro P; Camino N; de Mendoza C; Valer L; Núñez M; Martín-Carbonero L; González-Lahoz J; Soriano V
    Int J Antimicrob Agents; 2002 Dec; 20(6):438-43. PubMed ID: 12458138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
    Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
    AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
    Fätkenheuer G; Theisen A; Rockstroh J; Grabow T; Wicke C; Becker K; Wieland U; Pfister H; Reiser M; Hegener P; Franzen C; Schwenk A; Salzberger B
    AIDS; 1997 Nov; 11(14):F113-6. PubMed ID: 9386799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
    Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
    Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
    Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term immunologic response in HIV-infected patients with CD4 cell counts Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
    Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
    Salmon-Céron D; Deleuze J; Coste J; Guerin C; Ginsburg C; Blanche P; Finkielsztejn L; Pecqueux L; Chaput S; Gorin I; Sicard D
    Ann Med Interne (Paris); 2000 Jun; 151(4):297-302. PubMed ID: 10922958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.
    Para MF; Glidden DV; Coombs RW; Collier AC; Condra JH; Craig C; Bassett R; Leavitt R; Snyder S; McAuliffe V; Boucher C
    J Infect Dis; 2000 Sep; 182(3):733-43. PubMed ID: 10950766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.